Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) Overview | 8 | 1 |
| Therapeutics Development | 9 | 4 |
| Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) Products under Development by Stage of Development | 9 | 1 |
| Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) Products under Development by Therapy Area | 10 | 1 |
| Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) Products under Development by Indication | 11 | 2 |
| Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) Pipeline Products Glance | 13 | 2 |
| Late Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) Products under Development by Companies | 15 | 5 |
| Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) Therapeutics Assessment | 20 | 4 |
| Assessment by Monotherapy/Combination Products | 20 | 1 |
| Assessment by Mechanism of Action | 21 | 1 |
| Assessment by Route of Administration | 22 | 1 |
| Assessment by Molecule Type | 23 | 1 |
| Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) Companies Involved in Therapeutics Development | 24 | 10 |
| Amgen Inc. | 24 | 1 |
| AstraZeneca Plc | 25 | 1 |
| Bayer AG | 26 | 1 |
| Curis, Inc. | 27 | 1 |
| GlaxoSmithKline Plc | 28 | 1 |
| Hutchison MediPharma Limited | 29 | 1 |
| Karus Therapeutics Limited | 30 | 1 |
| Novartis AG | 31 | 2 |
| PIQUR Therapeutics AG | 33 | 1 |
| Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) Drug Profiles | 34 | 25 |
| AZD-8186 Drug Profile | 34 | 1 |
| BAY-1082439 Drug Profile | 35 | 1 |
| buparlisib hydrochloride Drug Profile | 36 | 5 |
| CUDC-907 Drug Profile | 41 | 5 |
| GSK-2636771 Drug Profile | 46 | 1 |
| HM-032 Drug Profile | 47 | 1 |
| KA-1463 Drug Profile | 48 | 1 |
| KA-2237 Drug Profile | 49 | 1 |
| KAR-4000 Drug Profile | 50 | 1 |
| PQR-309 Drug Profile | 51 | 3 |
| Small Molecule to Inhibit PI3K Beta for Bleeding and Clotting Disorders Drug Profile | 54 | 1 |
| Small Molecule to Inhibit PI3K Beta/Delta for Rheumatoid Arthritis Drug Profile | 55 | 1 |
| Small Molecule to Inhibit PI3K for Prostate Cancer Drug Profile | 56 | 1 |
| Small Molecules to Inhibit Pan PI3K for Ovarian Cancer Drug Profile | 57 | 1 |
| SRX-2523 Drug Profile | 58 | 1 |
| Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) Dormant Projects | 59 | 3 |
| Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) Discontinued Products | 62 | 1 |
| Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) Featured News &Press Releases | 63 | 12 |
| Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association | 63 | 1 |
| Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting | 63 | 1 |
| Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting | 63 | 1 |
| Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology | 64 | 1 |
| Jan 11, 2016: Seahorse Bioscience XF Technology Reaches 500th Citation in Cancer Research | 64 | 1 |
| Dec 06, 2015: Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting | 65 | 2 |
| Nov 05, 2015: Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting | 67 | 1 |
| Jun 10, 2015: Curis to Present CUDC-907 Clinical Data at the 20th Congress of the European Hematology Association and the 13th International Congress on Malignant Lymphoma | 67 | 1 |
| May 31, 2015: Curis Reports CUDC-907 Data From the Ongoing Phase 1 Trial at the 2015 ASCO Annual Meeting | 68 | 1 |
| May 27, 2015: PIQUR announces positive Phase 1 study results and the start of Phase 2 of PQR309 | 69 | 1 |
| May 20, 2015: Curis Announces Presentations of CUDC-907 Clinical Data at 2015 ASCO Annual Meeting | 70 | 1 |
| Apr 21, 2015: SignalRx Presents at 10th Annual Drug Discovery Chemistry Conference on its Dual Kinase-Epigenetic Inhibitors for Treating Cancer | 71 | 1 |
| Apr 17, 2015: PIQUR to present posters on its lead compound PQR309 at AACR Annual Meeting 2015 | 71 | 1 |
| Apr 06, 2015: Curis Announces Orphan Drug Designation for CUDC-907 in Diffuse Large B-Cell Lymphoma | 72 | 1 |
| Dec 18, 2014: Curis Announces Dosing of First Patient in Phase 1 Trial of CUDC-907 in Patients With Advanced/ Relapsed Solid Tumors | 73 | 2 |
| Appendix | 75 | 2 |
| Methodology | 75 | 1 |
| Coverage | 75 | 1 |
| Secondary Research | 75 | 1 |
| Primary Research | 75 | 1 |
| Expert Panel Validation | 75 | 1 |
| Contact Us | 75 | 1 |
| Disclaimer | 76 | 1 |